Synthetic studies on selective adenosine A2A receptor antagonists. Part II: Synthesis and structure-activity relationships of novel benzofuran derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3768-3771

  Saku, Osamu ^a   Saki, Mayumi ^a   Kurokawa, Masako ^a   Ikeda, Ken ^a   Uchida, Shin Ichi ^a   Takizawa, Takuya ^a   Uesaka, Noriaki ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

A2A; A2A Antagonist; A2A Receptor; A2A Receptor antagonist; Adenosine; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 MORPHOLINOBENZOFURAN DERIVATIVE; 4 PHENYLBENZOFURAN DERIVATIVE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; BENZOFURAN DERIVATIVE; PHENYL GROUP; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SYNTHESIS; HYDROGENATION; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZOFURANS; BIOLOGICAL AVAILABILITY; CALLITHRIX; MOTOR SKILLS DISORDERS; RECEPTOR, ADENOSINE A2A; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

CALLITHRIX JACCHUS;

EID: 77954215884     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.058     Document Type: Article

References (23)

1. B.B. Fredholm, R.A. Cunha, and P. Svenningsson Curr. Top. Med. Chem. 3 2003 413
2. P. Richardson, H. Kase, and P. Jenner Trends Pharmacol. Sci. 18 1997 338
3. T. Kanda, M. Jackson, L. Smith, R. Pearce, J. Nakamura, H. Kase, Y. Kuwana, and P. Jenner Ann. Neurol. 43 1998 507
4. M.A. Schwarzschild, J.-F. Chen, and A. Ascherio Neurology 58 2002 1154
5. G.C. Cotzias, P.S. Papavasiliou, and R. Gellene N. Eng. J. Med. 280 1969 337
6. A. Barbeau Can. Med. Assoc. J. 101 1969 59
7. U.K. Rinne Acta Neurol. Scand., Suppl. 95 1983 19
8. H. Kase, A. Mori, and P. Jenner Drug Discovery Today: Ther. Strateg. 1 2004 51
9. K. Xu, E. Bastia, and M. Schwarzschild Pharmacol. Ther. 105 2005 267
10. P.A. LeWitt, M. Guttman, J.W. Tetrud, P.J. Tuite, A. Mori, P. Chaikin, and N.M. Sussman Ann. Neurol. 63 2008 295
11. C.B. Vu Curr. Opin. Drug Discov. Devel. 8 2005 458
12. B. Cacciari, G. Pastori, and G. Spalluto Curr. Top. Med. Chem. 3 2003 403
13. O. Yuzlenko, and K. Kiec-Kononowicz Curr. Med. Chem. 13 2006 3609
14. K.A. Jacobson, and A.-G. Gao Nat. Rev. Drug Disc. 5 2006 247
15. O. Saku, M. Saki, M. Kurokawa, K. Ikeda, T. Takizawa, and N. Uesaka Bioorg. Med. Chem. Lett. 20 2010 1090
16. S. Ferré, A. Rubio, and K. Fuxe Neurosci. Lett. 130 1991 162
17. T. Kanda, S. Shiozaki, J. Shimada, F. Suzuki, and J. Nakamura Eur. J. Pharmacol. 256 1994 264
18. R.S. Obach, J.G. Baxter, T.E. Liston, B.M. Silber, B.C. Jones, F. Macintype, D.J. Rance, and P. Wastall J. Pharmacol. Exp. Ther. 283 1997 46
19. P.A. Loschmann, L.A. Smith, K.W. Lange, P. Jenner, and C.D. Marsden Psychopharmacology 109 1992 49
20. R.K.B. Pearce, M.J. Jackson, L.A. Smith, P. Jenner, and C.D. Marsden Mov. Disord. 10 1995 731
21. L.A. Smith, A. Gordin, P. Jenner, and C.D. Marsden Mov. Disord. 12 1997 935
22. The motor disability score was evaluated using the rating scale as described in detail in Ref. 10. Trained observers continuously monitored the animals for scoring periods and scored them every 10 min.
23. +.